Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells $479,520.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) Director William Burke sold 18,000 shares of the stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $26.64, for a total value of $479,520.00. Following the completion of the transaction, the director directly owned 23,022 shares in the company, valued at $613,306.08. This represents a 43.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

CeriBell Stock Performance

CeriBell stock opened at $26.14 on Monday. The company has a quick ratio of 7.79, a current ratio of 8.18 and a debt-to-equity ratio of 0.17. CeriBell, Inc. has a 52 week low of $12.40 and a 52 week high of $28.89. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -13.47 and a beta of 0.86. The stock has a 50-day moving average price of $25.52 and a 200 day moving average price of $21.04.

CeriBell (NASDAQ:CBLL – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. The firm had revenue of $29.34 million during the quarter, compared to analysts’ expectations of $29.18 million. Sell-side analysts anticipate that CeriBell, Inc. will post -2.05 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on CBLL shares. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. Raymond James Financial reiterated a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a research note on Thursday, September 3rd. BTIG Research reissued a “buy” rating on shares of CeriBell in a report on Wednesday, November 4th. Finally, Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CeriBell presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.25.

Read Our Latest Stock Analysis on CBLL

Institutional Trading of CeriBell

A number of hedge funds have recently modified their holdings of the stock. Sei Investments Co. grew its position in shares of CeriBell by 2.3% during the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock valued at $923,000 after acquiring an additional 1,125 shares during the period. Legal & General Group Plc acquired a new position in CeriBell in the 2nd quarter worth about $53,000. State of Wyoming acquired a new position in CeriBell in the 1st quarter worth about $62,000. Quantinno Capital Management LP raised its holdings in CeriBell by 3.0% in the 1st quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock worth $2,573,000 after purchasing an additional 4,119 shares during the period. Finally, Wellington Management Group LLP boosted its position in CeriBell by 5.5% during the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after purchasing an additional 4,572 shares in the last quarter.

About CeriBell

(Get Free Report)

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.

Featured Articles

Insider Buying and Selling by Quarter for CeriBell (NASDAQ:CBLL)

Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.